RxDoctor Payments Data

Gayleen Prausa, PA

Medical · Monument, CONPI 1528286192

Payments from drug & device makers

$2,827in general payments, 2019–2025

Across 138 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$876
  • Johnson & Johnson$460
  • Takeda Pharmaceuticals U.S.A., Inc.$244
  • Medtronic$143
  • Sanofi$130
  • Ardelyx, Inc.$127
  • plus $847 from 18 others

What the payments were for

  • Food & beverage$2,72796%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,827 in reported general payments places this provider in the 80th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$45,158
Medicare patients
284
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$482,268
CreonLipase/Protease/Amylase26$129,650
XifaxanRifaximin37$109,234
LinzessLinaclotide103$73,145
TrulancePlecanatide20$18,640
MotegrityPrucalopride Succinate26$16,322
Mesalamine24$14,195
Omeprazole277$5,335
Dexlansoprazole DrDexlansoprazole14$4,804
Budesonide DrBudesonide25$2,975
Colestipol Hcl37$2,734
Pantoprazole Sodium125$1,836
Ursodiol17$1,739
Esomeprazole Magnesium49$1,683
CholestyramineCholestyramine (With Sugar)11$1,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$460$482,26811 claims
AbbVieCreon, Linzess$876$202,795129 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$106$127,87457 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$244$16,32226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 766 medical providers in Colorado.

Other medical in Monument

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →